SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2

Clinical trials for SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2 explained in plain language.

Never miss a new study

Get alerted when new SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2 trials appear

Sign up with your email to follow new studies for SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug duo aims to stop aggressive cervical cancer from coming back

Disease control Not yet recruiting

This study is testing if adding two drugs, pembrolizumab and lenvatinib, after standard chemoradiation and brachytherapy can better control high-risk, locally advanced cervical cancer and prevent it from returning. It will involve about 87 adults with specific high-risk forms of …

Matched conditions: SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2

Phase: PHASE2 • Sponsor: Prof. Dr. Remi A. Nout • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2

Get alerted when new SQUAMOUS CELL CARCINOMA FIGO 2018 STAGE IIIA, IIIB, IIIC1-IIIC2 trials appear

New drug duo aims to stop aggressive cervical cancer from coming back